【OVERVIEW】 VISEN Pharmaceuticals (Taiwan) Ltd. is committed to the treatment of endocrine-related diseases, introducing the world’s leading treatment methods and drugs into the Taiwan market and hoping to provide more patients quick access to the world's advanced and reliable treatment solutions. In 2018, VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China, which includes Taiwan, Hong Kong, Macau, and mainland China. Ascendis Pharma, headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California, is a leading fully integrated biopharmaceutical company that uses its innovative platform technology to make a real difference to patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon™ technologies to create new, potentially best-in-class therapies. Founded in 1996, Vivo Capital is a global healthcare investment firm focused on investing in and building high quality companies. Vivo Capital is headquartered in Palo Alto, California, with offices in Taipei, Hong Kong, Shanghai, and Beijing. 【VALUE】 Innovation: Committed to bring innovative medications to the Greater China. Collaboration: Close collaboration with local government, research institutes and medical societies to provide medical solution to unmet clinical needs Effectiveness: To rapidly commercialize targeted new drugs and medications under challenging regulatory environment and market access.